CD47-SIRPα: A Pivotal Signaling Pathway for Targeting Immunotherapy in Non-Small Cell Lung Cancer.

IF 3.5 4区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Current medicinal chemistry Pub Date : 2025-09-29 DOI:10.2174/0109298673383976250911101532

Luying Zhang, Xueqin Wu, Mingyue Zhu, Yuli Zhou, Kun Liu, Bo Lin, Mengsen Li

引用次数: 0

Abstract

Non-Small Cell Lung Cancer (NSCLC) remains a major oncologic challenge with high mortality. The CD47-SIRPα pathway is critical for tumor immune escape by mediating "don't eat me" signaling. Despite progress, the specific mechanism of action of this pathway in NSCLC remains unclear, and the specific role of the CD47-signal in regulating immune escape needs to be further explored. This paper comprehensively analyzes the latest research progress on the CD47-SIRPα signaling pathway in NSCLC, as well as the challenges of CD47-SIRPα as a potential therapeutic target.

查看原文本刊更多论文

CD47-SIRPα：非小细胞肺癌靶向免疫治疗的关键信号通路

非小细胞肺癌（NSCLC）仍然是一个具有高死亡率的主要肿瘤挑战。CD47-SIRPα通路通过介导“不要吃我”信号通路对肿瘤免疫逃逸至关重要。尽管取得了进展，但该通路在NSCLC中的具体作用机制尚不清楚，cd47信号在调节免疫逃逸中的具体作用有待进一步探索。本文全面分析了CD47-SIRPα信号通路在NSCLC中的最新研究进展，以及CD47-SIRPα作为潜在治疗靶点所面临的挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current medicinal chemistry 医学-生化与分子生物学

CiteScore

8.60

自引率

2.40%

发文量

468

审稿时长

3 months

期刊介绍： Aims & Scope Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.